Trial Profile
Phase III study of HFT-290 in pediatric patients with cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Registrational
- Sponsors Hisamitsu Pharmaceutical
- 25 Aug 2022 According to a Kyowa Kirin media release, company has received a partial change approval for the additional indications of cancer pain relief for pediatric patients for FENTOS Tapes, transdermal, pain management patch.
- 16 Nov 2021 Results published in the Clinical Drug Investigation
- 10 Sep 2020 According to a Hisamitsu Pharmaceutical media release, company has submitted a new drug application for the additional indications of cancer pain relief for pediatric patients for FentosTape in Japan.